Equity Research Scientific & Technical Instruments

Should You Buy Novanta Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 10/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Novanta Inc. (NOVT) is rated as a strong fundamental performer with a QOC score of 8.2/10. Trading at $138.23, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.

The short answer: 1 of 10 CirclFi valuation models project upside for Novanta Inc. (NOVT) at $138.23 — the model consensus leans bearish, with a Quality Score of 8.2/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 9 of 10 models suggest overvaluation — majority bearish
  • Quality Score: 8.2/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 26/100 — Low — manageable risk
  • Fair Value Range: $10.68 – $158.36 (1383% spread)

Bullish Models

1 / 10

Bearish Models

9 / 10

Quality Score

8.2 /10

Excellent — top-tier fundamentals

Value Trap Risk

26 /100
Low

Low — manageable risk

Model Consensus

10 /13
Active Models

Avg. confidence: 54%

What Is the Investment Case for Novanta Inc. (NOVT) in 2026?

What Is the Bull Case vs the Bear Case for Novanta Inc. (NOVT)?

Bull case versus bear case for Novanta Inc. (NOVT) at $138.23, derived from 10 active CirclFi valuation models on 2026-09-15.
Bull case — $158.36 target (+14.6%) Bear case — $10.68 target (-92.3%)
According to the CirclFi Quality of Company (QOC) framework, Novanta Inc.'s rating of 8.2/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $10.68 (-92.3%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +106.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does NOVT Compare to Its Scientific & Technical Instruments Peers?

CGNX Cognex Corporation
8.3
VNT Vontier Corporation
8.1
ITRI Itron, Inc.
8.5
TRMB Trimble Inc.
8.1
MLAB Mesa Laboratories, I
8.5
FTV Fortive Corporation
8.0
LCTC Lifeloc Technologies
6.8
FCUV Focus Universal Inc.
5.1

Valuation data pages: CGNX · VNT · ITRI · TRMB · MLAB · FTV · LCTC · FCUV · ACFN · BMI

Which Other Stocks Score Like NOVT on Quality?

Closest companies to NOVT’s Quality of Company score of 8.2/10, across all industries.

Why Do CirclFi’s 10 Models Disagree on NOVT?

Spread

1383%

Fair Value Range

$10.68 – $158.36

A 1383% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Regime Cross

$158.36 (+14.6%)

Most Bearish

ML-RIV

$10.68 (-92.3%)

What Are the Biggest Risks of Buying NOVT Stock?

Model Disagreement

1383% spread signals high variance in projections.

Bearish Consensus

9/10 models suggest overvaluation.

Macro/Sector Risk

Scientific & Technical Instruments headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View NOVT Data Page →

So Is Novanta Inc. (NOVT) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Novanta Inc. at $138.23. 9/10 models flag overvaluation, median fair value sits at $48.63 (-64.8%), and the risk-reward profile appears unfavorable. Quality at 8.2/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Novanta Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About NOVT Stock?

Should I buy NOVT stock right now?

Based on CirclFi's multi-model analysis, 1 of 10 models see upside for NOVT at $138.23. The models are divided, which means the investment case depends heavily on your assumptions about Novanta Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Novanta Inc.?

Key risks include: wide model disagreement (1383% spread), signaling high uncertainty; general market and sector-specific risks affecting Scientific & Technical Instruments companies. Always diversify and consult a financial advisor.

How does NOVT compare to its competitors?

Among Scientific & Technical Instruments peers, NOVT holds a Quality Score of 8.2/10. Comparable companies include CGNX (QOC 8.3), VNT (QOC 8.1), ITRI (QOC 8.5). The relative ranking helps investors identify whether NOVT offers better fundamental quality than alternatives in the same sector.

Is NOVT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NOVT's Quality Score of 8.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy NOVT at?

CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $10.68 to $158.36. At $138.23, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for NOVT.

View NOVT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →